Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma.

Jaekyung CheonHyeyeong KimHan Sang KimChang Gon KimIlhwan KimBeodeul KangChan KimSanghoon JungYeonjung HaHong Jae Chon

Published in: Therapeutic advances in medical oncology (2023)

In the Child-Pugh B subgroup of patients with advanced HCC, Ate/Bev treatment showed modest clinical activity. However, due to the increased frequency of serious AEs, careful evaluation of treatment response and AE management is required in this subgroup of patients.

Keyphrases

end stage renal disease
mental health
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
combination therapy
metastatic colorectal cancer